Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | SNCA | P37840 | 1/20 | 0.40 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.37 |
| ▸ | MLYCD | O95822 | 1/20 | 0.36 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CLK1 | P49759 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.34 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.33 |
| ▸ | WNT3A | P56704 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7374828 | 0.82 | P2RX7 (0.52) | P2RX7KMT2AMEN1SNCAAHR | |
| SCHEMBL6602091 | 0.78 | P2RX7 (0.56) | P2RX7KMT2AMEN1AHRFAAH | |
| SCHEMBL8374791 | 0.78 | KDM4E (0.45) | KMT2AMEN1TRPM8MLYCDCYP1A2 | |
| SCHEMBL306106 | 0.77 | ALDH1A1 (0.53) | KMT2AMEN1CES1GAA | |
| SCHEMBL27539765 | 0.77 | P2RX7 (0.55) | P2RX7KMT2AMEN1AHRFAAH | |
| Hydrochloric Acid SCHEMBL29205819 | 0.77 | P2RX7 (0.55) | P2RX7KMT2AMEN1AHRFAAH | |
| SCHEMBL30963925 | 0.74 | P2RX7 (0.51) | P2RX7FAAHCES1CTDSP1CYP1A2 | |
| SCHEMBL24724207 | 0.74 | MLYCD (0.37) | KMT2AMEN1FAAHTRPM8MLYCD | |
| SCHEMBL30003812 | 0.74 | MLYCD (0.37) | KMT2AMEN1FAAHTRPM8MLYCD | |
| SCHEMBL5026814 | 0.74 | P2RX7 (0.55) | P2RX7KMT2AMEN1SNCAAHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120040441-A | Compositions and methods for treating cancer | A2A制药有限公司 | 2025-05-27 | — | — | CN | disclosed |
| CN-119522217-A | Compositions and methods for treating cancer | A2A制药有限公司 | 2025-02-25 | — | — | CN | disclosed |
| EP-3938364-B1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | ALTERITY THERAPEUTICS LTD (AU) | 2023-08-23 | — | — | EP | disclosed |
| EP-3938364-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | Alterity Therapeutics Limited (AU) | 2022-01-19 | — | — | EP | disclosed |
| CN-113811533-A | Compounds and methods for treating diseases | 艾特里提治疗有限公司 | 2021-12-17 | — | — | CN | disclosed |
| US-10941143-B2 | Imidazo [1,5-a]pyridine compounds and their use | Alterity Therapeutics Limited (AU) | 2021-03-09 | — | — | US | disclosed |
| US-10941143-B2 | Imidazo [1,5-a]pyridine compounds and their use | Alterity Therapeutics Limited (AU) | 2021-03-09 | — | — | US | disclosed |
| WO-2020186291-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | Alterity Therapeutics Limited (AU) | 2020-09-24 | — | — | WO | disclosed |
| US-20200291021-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | Alterity Therapeutics Limited (AU) | 2020-09-17 | — | — | US | disclosed |
| US-20200291021-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | Alterity Therapeutics Limited (AU) | 2020-09-17 | — | — | US | disclosed |
| US-8633212-B2 | Inhibitors of beta-secretase | VITAE PHARMACEUTICALS, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-8633212-B2 | Inhibitors of beta-secretase | VITAE PHARMACEUTICALS, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-8633212-B2 | Inhibitors of beta-secretase | VITAE PHARMACEUTICALS, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| EP-2406240-A2 | INHIBITORS OF BETA-SECRETASE | Vitae Pharmaceuticals, Inc. (US) | 2012-01-18 | — | — | EP | disclosed |
| US-20110245224-A1 | FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2011-10-06 | — | — | US | disclosed |
| US-20110071126-A1 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, INC. | 2011-03-24 | — | — | US | disclosed |
| US-20110071126-A1 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, INC. | 2011-03-24 | — | — | US | disclosed |
| US-20110071126-A1 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, INC. | 2011-03-24 | — | — | US | disclosed |
| WO-2010105179-A2 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010105179-A2 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10941143-B2 | Imidazo [1,5-a]pyridine compounds and their use | SNCA, PARK7, HTT | P2RX7 3381/4885KMT2A 654/4885MEN1 2116/4885 |
| US-20110245224-A1 | FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | SDHB, SDHA, RORC | P2RX7 2685/4885KMT2A 3960/4885MEN1 1594/4885 |
| US-20200291021-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | SNCA, HTT, PARK7 | P2RX7 4460/4885KMT2A 555/4885MEN1 1136/4885 |
| US-20110071126-A1 | INHIBITORS OF BETA-SECRETASE | BACE1, BACE2, PSEN1 | P2RX7 3251/4885KMT2A 3063/4885MEN1 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.